The Epigenetic Regulatory Role of P-element Induced Wimpy Testis (Piwi) Interacting RNA-823 (piR-823) in Ovarian Cancer Progression
NCT06320418 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 56
Last updated 2024-03-20
Summary
Ovarian cancer (OC) has one of the highest mortality rates for female malignant tumors, attributed to advanced cancer stages upon diagnosis as well as a high recurrence rate. Piwi-interacting RNA-823 (piR-823) is a single-stranded non-protein coding RNA (ncRNA) star molecule in epigenetics research. Extensive cellular regulatory functions and aberrant expression of piR-823 have been implicated in carcinogenesis. Therefore, the findings of piwi-ncRNA dysregulated-expression in OC Egyptian female patients' cohort could be employed as a potential novel mechanism for OC precision, a step toward ncRNA-precision
Conditions
Sponsors & Collaborators
-
Ain Shams University
lead OTHER
Principal Investigators
-
Nadia Hamdy, PhD · faculty of pharmacy Ain Shams university
Eligibility
- Sex
- FEMALE
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2022-06-15
- Primary Completion
- 2023-12-10
- Completion
- 2024-06-30
Countries
- Egypt
Study Locations
More Related Trials
-
Non-coding RNA in the Exosome of the Epithelia Ovarian Cancer
NCT03738319 ·Status: UNKNOWN
-
Letrozole in Patients With Ovarian Tumors
NCT00505661 ·Status: TERMINATED ·Phase: PHASE2
-
The Correlation Between HRD Detection and the Efficacy of PARP Inhibitors in Ovarian Cancer
NCT06242392 ·Status: NOT_YET_RECRUITING
-
Safety and Efficacy of Interferon Gamma-1b Plus Chemotherapy for Ovarian and Peritoneal Cancer
NCT00047632 ·Status: TERMINATED ·Phase: PHASE3
-
PTEN and IGFBP-3 Correlation in Ovarian Carcinoma Invasion
NCT00173407 ·Status: WITHDRAWN ·Phase: NA
-
HRD and Resistance to PAPPi in EOC Patients
NCT05310370 ·Status: UNKNOWN
-
Research Study in Patients With Advanced Ovarian Epithelial Cancer
NCT00053235 ·Status: WITHDRAWN
-
A Phase 1 Study of the Safety and Pharmacokinetics of AGS-8M4 in Subjects With Advanced Ovarian Cancer
NCT00816764 ·Status: COMPLETED ·Phase: PHASE1
-
Secondary Cytoreductive Surgery in Platinum-resistant Recurrent Ovarian Cancers
NCT04795596 ·Status: WITHDRAWN ·Phase: PHASE2/PHASE3
-
Evaluation of the Proliferative Activities of Insulin Analogues in Primary Human Tumor Cells
NCT01267461 ·Status: AVAILABLE
-
OSCA - Olaparib Standard of CAre Study
NCT02262273 ·Status: COMPLETED
-
MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer
NCT02364713 ·Status: TERMINATED ·Phase: PHASE2
-
Breast Cancer After Ovarian Cancer During and/or After Therapy: Genomic Evaluation
NCT05763472 ·Status: UNKNOWN
-
The IGF Axis Involvement in Immune Tumor Microenvironment in Ovarian Cancer and Its Clinical Significance
NCT03846856 ·Status: UNKNOWN
-
Ovarian Cancer Treatment With a Liposome Formulated mRNA Vaccine in Combination With (Neo-)Adjuvant Chemotherapy
NCT04163094 ·Status: TERMINATED ·Phase: PHASE1
-
Adoptive T Cell Therapy in Patients With Recurrent Ovarian Cancer
NCT04072263 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian Cancer
NCT05226507 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Screening for Ovarian Malignancy
NCT06348784 ·Status: COMPLETED
-
DNA Single Nucleotide Polymorphisms as Predictors of Toxicity
NCT02478476 ·Status: UNKNOWN
-
Safety and Efficacy of FolateScan (Technetium Tc 99m EC20) in Women With Suspected Ovarian or Endometrial Cancer
NCT01686256 ·Status: COMPLETED ·Phase: PHASE1
-
A Study Evaluating the Safety and Pharmacokinetics of DMUC4064A in Participants With Platinum-Resistant Ovarian Cancer or Unresectable Pancreatic Cancer
NCT02146313 ·Status: COMPLETED ·Phase: PHASE1
-
Search for Predictors of Therapeutic Response in Ovarian Carcinoma
NCT01391351 ·Status: COMPLETED ·Phase: NA
-
Effects of Cytotoxic Chemotherapy and PARP Inhibition on the Genomic Contexture of Ovarian Cancer
NCT04752865 ·Status: UNKNOWN
-
An Exploratory Study of HRD Score in Chinese Ovarian Cancer Patients Benefiting From PARP Inhibitor Targeted Therapy
NCT05255861 ·Status: UNKNOWN
-
Contrast-Enhanced Ultrasonography in Diagnosing Early-Stage Ovarian Cancer in Patients With an Adnexal Mass Undergoing Surgery to Remove the Ovary
NCT00626873 ·Status: COMPLETED ·Phase: PHASE1